London’s Claret Capital Partners closes Fund IV at €575 million to back European tech, life sciences and impact companies
Claret Capital Partners, a London-based independent growth debt fund manager, today announced the final close of its Claret European Growth Capital Fund IV (Fund IV), which has now raised €575 million in total, surpassing Claret’s original €500 million target.
The €575 million total comprises €440 million in Fund IV commitments and €135 million in an affiliated discretionary mandate. The firm states that Fund IV attracted increased commitments from Claret’s institutional investor base, including pension plans, insurance companies, family offices, and other leading public and institutional investors, as well as from private wealth investors (via an ELTIF structure). It will also benefit from a series of discretionary co-investment partnerships. This fundraising brings Claret’s total capital raised since inception to €1.3 billion.
David Bateman, Managing Partner at Claret Capital Partners, commented, “To have raised this amount not only validates our approach and track record but is also a massive vote of confidence for the European technology, life sciences and impact ecosystems. With a growing pipeline of high-quality opportunities, the team is actively deploying capital and continuing to look for great entrepreneurs building the next generation of European champions.”
Since 2013, the firm has invested over €1.5 billion through its funds, supporting more than 210 companies across the technology, life sciences and impact sectors. The firm states that its team has been active in technology financing markets for over 25 years, providing debt solutions that help entrepreneurs and their investors grow their companies while minimising dilution.
According to the firm, loans typically range from €2 million to €100 million, with each opportunity evaluated on a case-by-case basis by its experienced investment professionals. It mentions that the capital can be used for organic growth, acquisitions, capital expenditure, working capital, research and development, geographical expansion, marketing and distribution channel maximisation, bridge loans extending cash runway to the next capital round, and can also support various forms of recapitalisation. The firm also provides bespoke advisory and fund management services across a range of funds.
Claret highlighted that 32% of Fund IV has already been deployed to back 27 companies, including Billie (B2B BNPL platform), Cinclus Pharma (clinical-stage pharmaceutical company), PRODA (commercial real estate software), Inventiva (clinical-stage biotech), and Surfe (B2B sales-intelligence platform).
In September 2025, the firm announced the second close of its Fund IV, bringing total commitments to over €350 million. In May 2023, Claret launched a new €72 million Opportunity Fund, earmarked to provide follow-on funding for its high-performing portfolio.
The final close of Fund III was held in 2022 with total commitments of €297 million and has since delivered an impressive track record of strategic exits, including European champions such as Cytora (acquired by Applied Systems), Endomag (acquired by Hologic, Inc.), Logpoint (acquired by Summa Equity), Lyst (acquired by ZOZO, Inc.), Tiqets (acquired by Expedia), as well as successful NASDAQ IPOs such as Abivax.
Johan Kampe, Managing Partner at Claret Capital Partners, commented, “It continues to be a true privilege to support the founders and entrepreneurs who are driving real innovation across Europe at a monumental time for both business and society. As equity markets remain more selective and founders look for ways to grow without unnecessary dilution, we expect demand for flexible, non-dilutive capital to keep accelerating – and Fund IV positions us to meet that demand at scale.”
Following this final close, Claret will continue to expand its pan-European platform, increasing local presence across the continent’s key innovation hubs, including new team members now based in Paris and soon in Berlin.
The post London’s Claret Capital Partners closes Fund IV at €575 million to back European tech, life sciences and impact companies appeared first on EU-Startups.